Glenview State Bank Trust DEPT. Has $9.19 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Glenview State Bank Trust DEPT. cut its position in Johnson & Johnson (NYSE:JNJ) by 0.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 71,030 shares of the company’s stock after selling 325 shares during the quarter. Johnson & Johnson comprises approximately 3.7% of Glenview State Bank Trust DEPT.’s holdings, making the stock its 6th biggest position. Glenview State Bank Trust DEPT.’s holdings in Johnson & Johnson were worth $9,190,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in JNJ. Virtus ETF Advisers LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $25,000. Krane Funds Advisors LLC acquired a new stake in shares of Johnson & Johnson during the second quarter worth $26,000. Financial Advantage Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter worth $28,000. Crewe Advisors LLC lifted its holdings in shares of Johnson & Johnson by 725.9% during the second quarter. Crewe Advisors LLC now owns 223 shares of the company’s stock worth $31,000 after buying an additional 196 shares in the last quarter. Finally, Eii Capital Management Inc. acquired a new stake in shares of Johnson & Johnson during the third quarter worth $39,000. 72.25% of the stock is owned by institutional investors and hedge funds.

JNJ stock opened at $133.00 on Friday. The company has a market cap of $343.25 billion, a PE ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The business has a 50-day simple moving average of $130.83 and a 200 day simple moving average of $134.05. Johnson & Johnson has a 52 week low of $121.00 and a 52 week high of $148.99. The company has a quick ratio of 1.00, a current ratio of 1.26 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion during the quarter, compared to the consensus estimate of $20.14 billion. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 earnings per share. On average, analysts anticipate that Johnson & Johnson will post 8.65 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $0.95 dividend. This represents a $3.80 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date of this dividend is Monday, November 25th. Johnson & Johnson’s dividend payout ratio is presently 46.45%.

A number of research firms have recently weighed in on JNJ. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Credit Suisse Group boosted their price target on Johnson & Johnson from $158.00 to $163.00 in a research note on Thursday, October 24th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $145.00 price target on shares of Johnson & Johnson in a research note on Tuesday, August 27th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, July 16th. Finally, Wells Fargo & Co dropped their price target on Johnson & Johnson from $157.00 to $155.00 and set an “outperform” rating for the company in a research note on Wednesday, October 16th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $151.64.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Percentage Gainers

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.